These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35264027)

  • 1. Statewide Assessment of the Hepatitis C Virus Care Cascade for Incarcerated Persons in Vermont.
    Hale AJ; Mathur S; Dejace J; Lidofsky SD
    Public Health Rep; 2023; 138(2):265-272. PubMed ID: 35264027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of treatment for hepatitis C in prisoners using a nurse-led, statewide model of care.
    Papaluca T; McDonald L; Craigie A; Gibson A; Desmond P; Wong D; Winter R; Scott N; Howell J; Doyle J; Pedrana A; Lloyd A; Stoove M; Hellard M; Iser D; Thompson A
    J Hepatol; 2019 May; 70(5):839-846. PubMed ID: 30654067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Previous incarceration impacts access to hepatitis C virus (HCV) treatment among HIV-HCV co-infected patients in Canada.
    Kronfli N; Nitulescu R; Cox J; Moodie EE; Wong A; Cooper C; Gill J; Walmsley S; Martel-Laferrière V; Hull MW; Klein MB;
    J Int AIDS Soc; 2018 Nov; 21(11):e25197. PubMed ID: 30460791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HCV spread among female incarcerated population and treatment pathways to viral elimination in Italian prison settings: clinical perspectives and medico legal aspects.
    Fiore V; Rastrelli E; Madeddu G; Ranieri R; De Vito A; Giuliani R; Di Mizio G; Bolcato M; De Matteis G; Ialungo AM; Dell'Isola S; Starnini G; Babudieri S
    BMC Infect Dis; 2022 Jul; 22(1):601. PubMed ID: 35799126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An intervention to increase hepatitis C virus diagnosis and treatment uptake among people in custody in Iran.
    Hariri S; Alavi M; Roshandel G; Mohammadi Z; Fazel A; Amiriani T; Bazazan A; Motamed-Gorji N; Sohrabpour A; Merat S; Poustchi H; Malekzadeh R
    Int J Drug Policy; 2021 Sep; 95():103269. PubMed ID: 33991887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
    Jacobson IM; Lawitz E; Kwo PY; Hézode C; Peng CY; Howe AYM; Hwang P; Wahl J; Robertson M; Barr E; Haber BA
    Gastroenterology; 2017 May; 152(6):1372-1382.e2. PubMed ID: 28193518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C treatment outcomes among patients treated in co-located primary care and addiction treatment settings.
    Ngo BV; James JR; Blalock KL; Jackson SL; Chew LD; Tsui JI
    J Subst Abuse Treat; 2021 Dec; 131():108438. PubMed ID: 34098298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
    Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era.
    Hariri S; Sharafi H; Sheikh M; Merat S; Hashemi F; Azimian F; Tamadoni B; Ramazani R; Gouya MM; Abbasi B; Tashakorian M; Alasvand R; Alavian SM; Poustchi H; Malekzadeh R
    Harm Reduct J; 2020 Oct; 17(1):80. PubMed ID: 33081794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study.
    Sheehan Y; Cunningham EB; Cochrane A; Byrne M; Brown T; McGrath C; Lafferty L; Tedla N; Dore GJ; Lloyd AR; Grebely J
    J Hepatol; 2023 Sep; 79(3):635-644. PubMed ID: 37116714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy.
    Macías J; Morano LE; Téllez F; Granados R; Rivero-Juárez A; Palacios R; Ríos M; Merino D; Pérez-Pérez M; Collado A; Figueruela B; Morano A; Freyre-Carrillo C; Martín JM; Rivero A; García F; Pineda JA;
    J Hepatol; 2019 Jul; 71(1):45-51. PubMed ID: 30853642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients.
    Wong YJ; Thurairajah PH; Kumar R; Fock KM; Law NM; Chong SY; Manejero FG; Ang TL; Teo EK; Tan J
    Clin Mol Hepatol; 2021 Jul; 27(3):474-485. PubMed ID: 33601868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained Virologic Response and Costs Associated with Direct-Acting Antivirals for Chronic Hepatitis C Infection in Oklahoma Medicaid.
    Pham TT; Keast SL; Farmer KC; Thompson DM; Rathbun RC; Nesser NJ; Holderread BP; Skrepnek GH
    J Manag Care Spec Pharm; 2018 Jul; 24(7):664-676. PubMed ID: 29952711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brief Report: HCV Universal Test-and-Treat With Direct Acting Antivirals for Prisoners With or Without HIV: A Prison Health Care Workers-Led Model for HCV Microelimination in Thailand.
    Supanan R; Han WM; Harnpariphan W; Ueaphongsukkit T; Ubolyam S; Sophonphan J; Tangkijvanich P; Thanprasertsuk S; Avihingsanon A;
    J Acquir Immune Defic Syndr; 2021 Dec; 88(5):465-469. PubMed ID: 34757974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time to complete hepatitis C cascade of care among patients identified during mass screening campaigns in rural Rwanda: a retrospective cohort study.
    Kamali I; Shumbusho F; Barnhart DA; Nyirahabihirwe F; Gakuru JP; Dusingizimana W; Nizeyumuremyi E; Habinshuti P; Walker S; Makuza JD; Serumondo J; Nshogoza Rwibasira G; Ndahimana JD
    BMC Infect Dis; 2022 Mar; 22(1):272. PubMed ID: 35313817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advancing Hepatitis C Elimination through Opt-Out Universal Screening and Treatment in Carceral Settings, United States.
    McNamara M; Furukawa N; Cartwright EJ
    Emerg Infect Dis; 2024 Apr; 30(13):S80-S87. PubMed ID: 38561831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of Direct-Acting Antiviral Treatment of Psychiatric Patients with Comorbid Hepatitis C Virus Infection.
    Gayam V; Jegede O; Tiongson B; Mandal AK; Sidhu J; Garlapati P
    Dig Dis; 2020; 38(3):232-239. PubMed ID: 31494648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis.
    Puoti M; Foster GR; Wang S; Mutimer D; Gane E; Moreno C; Chang TT; Lee SS; Marinho R; Dufour JF; Pol S; Hezode C; Gordon SC; Strasser SI; Thuluvath PJ; Zhang Z; Lovell S; Pilot-Matias T; Mensa FJ
    J Hepatol; 2018 Aug; 69(2):293-300. PubMed ID: 29551706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?
    Christensen S; Buggisch P; Mauss S; Böker KHW; Schott E; Klinker H; Zimmermann T; Weber B; Reimer J; Serfert Y; Wedemeyer H
    Addiction; 2018 May; 113(5):868-882. PubMed ID: 29359361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of the hepatitis C testing, care and treatment program in the country of Georgia's corrections system, December 2013 - April 2015.
    Harris AM; Chokoshvili O; Biddle J; Turashvili K; Japaridze M; Burjanadze I; Tsertsvadze T; Sharvadze L; Karchava M; Talakvadze A; Chakhnashvili K; Demurishvili T; Sabelashvili P; Foster M; Hagan L; Butsashvili M; Morgan J; Averhoff F
    BMC Public Health; 2019 May; 19(Suppl 3):466. PubMed ID: 32326938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.